- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Accommodating, multifocal IOLs make effective combination, study finds
Results of a retrospective study show good visual acuity outcomes at near, intermediate, and distance, and high rates of satisfaction can be achieved using a strategy combining an accommodating IOL (crystalens, eyeonics) in one eye with the apodized diffractive multifocal IOL (AcrySof ReSTOR, Alcon Laboratories) in the other eye in patients undergoing cataract surgery or a clear lens exchange procedure.
Key Points
San Diego-Implanting an accommodating IOL (AT-45 crystalens, eyeonics) and an apodized diffractive multifocal IOL (AcrySof ReSTOR, Alcon Laboratories) in fellow eyes may be an effective approach for expanding the focal range of vision in patients undergoing cataract surgery or a clear lens exchange procedure, said Randy T. Jackson, MD, here at the annual meeting of the American Society of Cataract and Refractive Surgery.
"We also found no significant difference between eyes with respect to visual symptoms, including blur, halo, glare, ghosting, and night or day driving. That was somewhat surprising since, overall, the patients favored the quality of vision in the eye with the accommodating IOL," Dr. Jackson said.
All patients in the study had at least 1 month of follow-up and received the accommodating IOL in the dominant eye and the clear, one-piece diffractive IOL in the non-dominant eye. Target refraction was –0.25 D for the eye with the accommodating lens and plano for the eye with the diffractive lens.
Preoperatively, best corrected visual acuity ranged from 20/15 to 20/60, spherical equivalent was between –9.00 D and +3.50 D, and mean astigmatism was just under 1.0 D. Maximum follow-up was approximately 13.5 months, with an average of approximately 4 months.
